[Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas]
- PMID: 16181544
[Hypermethylation of fragile histidine triad gene and 3p14 allelic deletion in ovarian carcinomas]
Abstract
Objective: The FHIT (fragile histidine triad) is a candidate tumor suppressor gene (TSG) located on chromosome 3p14.2. Hypermethylation and loss of heterozygosity (LOH) are major mechanisms in the inactivation of tumor suppressor genes. In this study, the methylation status of FHIT and LOH of 3p14 in 61 cases of human sporadic ovary carcinomas were investigated.
Methods: Sixty-one primary ovary carcinomas and 10 borderline ovarian tumors were analyzed with methylation specific PCR (MSP) to detect the CpG island methylation status in the FHIT promoter region. In addition, 45 cases of ovary carcinomas and their corresponding non-tumor ovary tissues were investigated with D3S1287 microsatellite polymorphic marker for LOH.
Results: Hypermethylation of FHIT gene was observed in 39.3% (24/61) of ovarian carcinomas. The frequencies of hypermethylation in serous ovarian carcinoma, mucinous ovarian carcinoma, endometrioid ovarian carcinoma and ovary borderline tumor were 45.2% (19/42), 14.3% (1/7), 33.3% (4/12) and 60.0% (6/10), respectively. Ten of twenty-three (43.5%) informative tumors showed LOH and 6 of 18 (33.3%) informative cases showed homozygous deletions. The status of FHIT methylation was not associated with clinical stage and differentiation grade, there was no significant difference between the malignant and borderline tumors.
Conclusion: Hypermethylation and allelic deletion of FHIT are frequent events in ovarian carcinomas and are important mechanisms for the loss of expression of this gene.
Similar articles
-
Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.Clin Cancer Res. 2002 Sep;8(9):2890-3. Clin Cancer Res. 2002. PMID: 12231533
-
Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.Mol Cancer Res. 2006 Feb;4(2):93-9. doi: 10.1158/1541-7786.MCR-05-0070. Mol Cancer Res. 2006. PMID: 16513840
-
Impaired FHIT expression characterizes serous ovarian carcinoma.Br J Cancer. 2001 Jul 20;85(2):247-54. doi: 10.1054/bjoc.2001.1886. Br J Cancer. 2001. PMID: 11461085 Free PMC article.
-
The Fragile Histidine Triad gene and breast cancer.Med Sci Monit. 2002 Jul;8(7):RA140-4. Med Sci Monit. 2002. PMID: 12118213 Review.
-
FHIT: doubts are clear now.ScientificWorldJournal. 2010 Jun 16;10:1142-51. doi: 10.1100/tsw.2010.110. ScientificWorldJournal. 2010. PMID: 20563537 Free PMC article. Review.
Cited by
-
DNA methylation of cancer genome.Birth Defects Res C Embryo Today. 2009 Dec;87(4):335-50. doi: 10.1002/bdrc.20163. Birth Defects Res C Embryo Today. 2009. PMID: 19960550 Free PMC article. Review.
-
DNA methylation in promoter region as biomarkers in prostate cancer.Methods Mol Biol. 2012;863:67-109. doi: 10.1007/978-1-61779-612-8_5. Methods Mol Biol. 2012. PMID: 22359288 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous